ArticleBMC microbiology2012
Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis.
Article in BMC microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers.Antimicrobial agents and chemotherapy · 2017Trial
- In silico analysis, expression, and characterization of LysStp1 endolysin with L-alanyl-D-glutamate carboxypeptidase activity.Virus genes · 2026Article
- Isolation and Characterization of A Novel Pbunavirus with Promising Antibiofilm Activity Against Pseudomonas Aeruginosa.Current microbiology · 2025Article
- Antibacterial activity of endolysin LysP70 fromFrontiers in microbiology · 2025Article
- Article
- Lysins as a powerful alternative to combat Bacillus anthracis.Applied microbiology and biotechnology · 2024Review
- Prophage-Derived Regions inInternational journal of molecular sciences · 2023Article
- Characterization of PlyB221 and PlyP32, Two Novel Endolysins Encoded by Phages Preying on theViruses · 2020Article
- Identification and in vitro Characterization of a Novel Phage Endolysin that Targets Gram-Negative Bacteria.Microorganisms · 2020Article
- Alternative Enzyme Protection Assay To Overcome the Drawbacks of the Gentamicin Protection Assay for Measuring Entry and Intracellular Survival of Staphylococci.Infection and immunity · 2019Article
- Genomic characterization of three novel Basilisk-like phages infecting Bacillus anthracis.BMC genomics · 2018Article
- Article
- Bacteriophages and Their Immunological Applications against Infectious Threats.Journal of immunology research · 2017Review
- Proteomic Analysis of a Novel Bacillus Jumbo Phage Revealing Glycoside Hydrolase As Structural Component.Frontiers in microbiology · 2016Article
- Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3.Virus genes · 2015Article
- Genomic analysis of a ginger pathogen Bacillus pumilus providing the understanding to the pathogenesis and the novel control strategy.Scientific reports · 2015Article
- Bacteriophage PBC1 and its endolysin as an antimicrobial agent against Bacillus cereus.Applied and environmental microbiology · 2015Article
- The novel Shewanella putrefaciens-infecting bacteriophage Spp001: genome sequence and lytic enzymes.Journal of industrial microbiology & biotechnology · 2014Article
- A functional peptidoglycan hydrolase characterized from T4SS in 89K pathogenicity island of epidemic Streptococcus suis serotype 2.BMC microbiology · 2014Article
- Possible use of bacteriophages active against Bacillus anthracis and other B. cereus group members in the face of a bioterrorism threat.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndolysins produced by bacteriophages lyse bacteria, and are thus considered a novel type of antimicrobial agent. Several endolysins from Bacillus phages or prophages have previously been characterized and used to target Bacillus strains that cause disease in animals and humans. B. thuringiensis phage BtCS33 is a Siphoviridae family phage and its genome has been sequenced and analyzed. In the BtCS33 genome, orf18 was found to encode an endolysin protein (PlyBt33).
resultsBioinformatic analyses showed that endolysin PlyBt33 was composed of two functional domains, the N-terminal catalytic domain and the C-terminal cell wall binding domain. In this study, the entire endolysin PlyBt33, and both the N- and C-termini,were expressed in Escherichia coli and then purified. The lytic activities of PlyBt33 and its N-terminus were tested on bacteria. Both regions exhibited lytic activity, although PlyBt33 showed a higher lytic activity than the N-terminus. PlyBt33 exhibited activity against all Bacillus strains tested from five different species, but was not active against Gram-negative bacteria. Optimal conditions for PlyBt33 reactivity were pH 9.0 and 50 °C. PlyBt33 showed high thermostability, with 40% of initial activity remaining following 1 h of treatment at 60 °C. The C-terminus of PlyBt33 bound to B. thuringiensis strain HD-73 and Bacillus subtilis strain 168. This cell wall binding domain might be novel, as its amino acid sequence showed little similarity to previously reported endolysins.
conclusionsPlyBt33 showed potential as a novel antimicrobial agent at a relatively high temperature and had a broad lytic spectrum within the Bacillus genus. The C-terminus of PlyBt33 might be a novel kind of cell wall binding domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.